KBC Group’s Iovance Biotherapeutics IOVA Stock Holding History

KBC Group’s Portfolio IOVA Stock Details IOVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$40K	Hold	9,586	–	–	﹤0.01%	1772
2026 Q1	$34K	Buy	+9,586	New	+$30.7K	﹤0.01%	1766
2025 Q2	–	Sell	-12,303	Closed	-$41K	–	1762
2025 Q1	$41K	Hold	12,303	–	–	﹤0.01%	1822
2024 Q4	$91K	Buy	12,303 +6,321	+106%	+$58.6K	﹤0.01%	1621
2024 Q3	$56K	Hold	5,982	–	–	﹤0.01%	1656
2024 Q2	$48K	Buy	5,982 +1,607	+37%	+$17.2K	﹤0.01%	1646
2024 Q1	$65K	Sell	4,375 -198	-4%	-$2.31K	﹤0.01%	1381
2023 Q4	$37K	Hold	4,573	–	–	﹤0.01%	1708
2023 Q3	$21K	Buy	+4,573	New	+$29.9K	﹤0.01%	1876
2020 Q4	–	Sell	-600	Closed	-$20K	–	1271
2020 Q3	$20K	Hold	600	–	–	﹤0.01%	1212
2020 Q2	$16K	Hold	600	–	–	﹤0.01%	1255
2020 Q1	$18K	Hold	600	–	–	﹤0.01%	1257
2019 Q4	$17K	Buy	600 +380	+173%	+$8.64K	﹤0.01%	1460
2019 Q3	$4K	Hold	220	–	–	﹤0.01%	1469
2019 Q2	$5K	Buy	+220	New	+$3.31K	﹤0.01%	1449

Other funds holding IOVA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

MFM

MHR Fund Management New York $1.92B AUM 119.57% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

KBC Group's IOVA Position: Q2 2026 in Review

KBC Group held its Iovance Biotherapeutics (IOVA) position steady in Q2 2026 at 9,586 shares worth $40K. The position accounts for ﹤0.01% of the portfolio, ranked #1772.

KBC Group first reported a position in IOVA in Q2 2019 and has held it in 15 quarters since. The position peaked at $91K in Q4 2024. 292 funds tracked by Wall St. Rank hold IOVA as of Q2 2026.

KBC Group held 9,586 shares of Iovance Biotherapeutics worth $40K as of Q2 2026.
KBC Group left its Iovance Biotherapeutics share count unchanged in Q2 2026.
Iovance Biotherapeutics made up ﹤0.01% of KBC Group's portfolio in Q2 2026, its #1772 holding.
KBC Group first reported a position in Iovance Biotherapeutics in Q2 2019 and has held it in 15 quarters since.
KBC Group's Iovance Biotherapeutics position peaked at $91K in Q4 2024.
292 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q2 2026.

Based on KBC Group's 13F filing for Q2 2026, filed 5 Aug 2026.